1. A Phase 1 Randomized Study of Single Intravenous Infusions of the Novel Nitroxyl Donor BMS‐986231 in Healthy Volunteers. (31st January 2019) Authors: Cowart, Douglas; Venuti, Robert P.; Lynch, Kim; Guptill, Jeffrey T.; Noveck, Robert J.; Foo, Shi Yin Journal: Journal of clinical pharmacology Issue: Volume 59:Number 5(2019) Page Start: 717 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Phase 2a dose‐escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS‐986231 in hospitalized patients with heart failure with reduced ejection fraction. (5th July 2017) Authors: Tita, Cristina; Gilbert, Edward M.; Van Bakel, Adrian B.; Grzybowski, Jacek; Haas, Garrie J.; Jarrah, Mohammad; Dunlap, Stephanie H.; Gottlieb, Stephen S.; Klapholz, Marc; Patel, Parag C.; Pfister, Roman; Seidler, Tim; Shah, Keyur B.; Zieliński, Tomasz; Venuti, Robert P.; Cowart, Douglas; Foo, Sh... Journal: European journal of heart failure Issue: Volume 19:Number 10(2017) Page Start: 1321 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. High frequency of anti-DSG 2 antibodies in post COVID-19 serum samples. (September 2022) Authors: Lee, Edward C.Y.; Tyler, Ryan E.; Johnson, Derrick; Koh, Natalie; Ong, Biauw Chi; Foo, Shi Yin; Tan, Jack W.C. Journal: Journal of molecular and cellular cardiology Issue: Volume 170(2022) Page Start: 121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗